The aim of the study was to determine the efficacy and toxicity of gemcitabine, cisplatin and paclitaxel (GCP) combination as a first salvage treatment of patients with relapsed GCT. Four courses of paclitaxel 175 mg/m(2) and cisplatin 50 mg/m(2), both on day 1, and gemcitabine 1000 mg/m(2), on days 1 and 8, every 3 weeks, were given to 12 consecutive patients who had failed standard 1st line treatment. Six patients (50%; 95% CI 21-79%) achieved favourable response and two of them are maintained 38+ and 29+ months. Median survival time was 16 months (range, 0.77-38+). All, but two patients had hematological toxicity Gr3-4 with infectious complication seen only in 6 courses of therapy. GCP is an active second-line combination regimen for relapsed GCTs with acceptable toxicity profile. However the results of this study did not show expected treatment efficacy and we raise the idea of cisplatin dosage relevance in this combination.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
BJU Int
April 2023
Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Article Synopsis
- The study aimed to evaluate the clinical benefits of administering chemotherapy after pembrolizumab treatment in patients with metastatic urothelial carcinoma, focusing on whether it can restore sensitivity to platinum-based drugs.
- Out of 236 patients who received pembrolizumab, 105 were analyzed for their survival outcomes, comparing those who continued with pembrolizumab versus those who received re-challenging chemotherapy after showing disease progression.
- Results indicated that patients who received re-challenging chemotherapy had a significantly longer median overall survival (13.9 months) compared to those who continued with pembrolizumab (5.8 months), suggesting the potential effectiveness of this treatment strategy.
Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.
Front Oncol
August 2022
Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: Gallbladder cancer (GBC) is highly malignant and is often diagnosed at the advanced stage. Lack of opportunity to surgery results in an unsatisfactory outcome. This pilot study employed gemcitabine combined with nab-paclitaxel (AG) as a conversion therapeutic measure for locally advanced GBC and successfully achieved conversion surgery in three initially unresectable GBC patients.
View Article and Find Full Text PDFThe Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis.
Front Oncol
February 2021
Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Background: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) for non-metastatic locoregionally advanced nasopharyngeal carcinoma (NPC) has gained considerable attention. However, the most efficacious IC regimens remain investigational. We aimed to compare the survival benefits of all available IC regimens followed by CCRT in this network meta-analysis.
View Article and Find Full Text PDFPatient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Cancer Biol Med
February 2021
National Chengdu Center for Safety Evaluation of Drugs and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610000, China.
Article Synopsis
- The study created a repository of patient-derived xenograft (PDX) models for non-small cell lung cancer (NSCLC) to investigate their ability to maintain tumor heterogeneity.
- The research involved implanting NSCLC specimens into mice, examining protein expression and conducting genetic analyses to confirm that PDX models mirrored the original patient tumors.
- The results demonstrated that PDX models effectively replicate the complex characteristics of NSCLC, proving useful for testing responses to various cancer treatments.
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
BMC Cancer
December 2018
Department of Internal Medicine I, University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Background: Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warranted.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!